Combination encorafenib plus binimetinib for unresectable/metastatic BRAF V600E or V600K-positive melanoma FDA approved

Non-Sponsored Content

By: scienterrific | Last updated: 2 July 2018 | In: Gastrointestinal Cancer, US FDA Onc\Haem Approvals, Oncology, Targeted Therapies

Article Keywords

V600E, V600K, Array BioPharma, Braftovi, encorafenib, Mektovi, melanoma, FDA, binimetinib, BRAF

On June 27th, the FDA approved Array Biomarpharma’s combination encorafenib (BRAFTOVI®) plus binimetinib (and MEKTOVI®) for patients with unresectable or metastatic melanoma harbouring a BRAF V600E or V600K mutation detected by an FDA-approved test.

Disclaimer

This article is not medical advice. Patients should seek personal assessment by a licenced specialist. Physicians are recommended to read the full publication(s) as cited in the article before making medical decisions. This article does not supersede nor replace the published article(s).

Non-Sponsored Content